Received Mar 31, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Suspected vaccination failure; got shingles twice after taking vaccine near his eye; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a male patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and facial herpes zoster (Verbatim: got shingles twice after taking vaccine near his eye). The outcome of the vaccination failure and facial herpes zoster were not reported. It was unknown if the reporter considered the vaccination failure and facial herpes zoster to be related to Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine. It was unknown if the company considered the facial herpes zoster to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 25-MAR-2026 This case was reported by a consumer via interactive digital media. The reporter stated that reporters neighbor got shingles twice after taking vaccine near his eye and he would not take any more vaccines ever now. This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for facial herpes zoster and laboratory confirmation regarding facial herpes zoster were unknown at the time of reporting. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Vaccination failure, on an unknown time after vaccination with unknown dose of Shingles vaccine, in a male patient. Based on the available information a possible causality that the event was caused by GSK vaccine product cannot be ascertained. Consent for further follow up has not been received.